Quart Barry D — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Quart Barry D has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.85M.

Profile

Quart Barry D

Barry D. Quart is a prominent executive in the pharmaceutical industry, currently serving as the CEO and a director of Kiniksa Pharmaceuticals International, plc. He has extensive experience in the biotech and pharmaceutical sectors, having held various leadership roles in multiple companies. Quart has been instrumental in the development and commercialization of innovative therapies.

RoleInsider
Notability75/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-06-02KNSAKiniksa Pharmaceuticals International, plcM — Option exercise2.8K—
2026-04-29KNSAKiniksa Pharmaceuticals International, plcS — Open-market sale13.1K$50.10$656K
2026-04-29KNSAKiniksa Pharmaceuticals International, plcM — Option exercise13.1K$14.33$188K
2026-04-08KNSAKiniksa Pharmaceuticals International, plcS — Open-market sale [10b5-1]6.9K$50.00$345K
2026-04-08KNSAKiniksa Pharmaceuticals International, plcM — Option exercise [10b5-1]6.9K$14.33$99K
2026-02-12KNSAKiniksa Pharmaceuticals International, plcS — Open-market sale [10b5-1]2.7K$45.00$121K
2026-02-12KNSAKiniksa Pharmaceuticals International, plcM — Option exercise [10b5-1]2.7K$15.47$42K
2026-02-12KNSAKiniksa Pharmaceuticals International, plcS — Open-market sale [10b5-1]110$45.00$5K
2026-02-12KNSAKiniksa Pharmaceuticals International, plcM — Option exercise [10b5-1]110$15.47$2K
2026-02-04KNSAKiniksa Pharmaceuticals International, plcS — Open-market sale [10b5-1]2.6K$45.02$117K
2026-02-04KNSAKiniksa Pharmaceuticals International, plcM — Option exercise [10b5-1]2.6K$15.47$40K
2026-02-04KNSAKiniksa Pharmaceuticals International, plcS — Open-market sale [10b5-1]12.5K$45.27$567K
2026-02-04KNSAKiniksa Pharmaceuticals International, plcM — Option exercise [10b5-1]12.5K$15.47$194K
2026-02-04KNSAKiniksa Pharmaceuticals International, plcS — Open-market sale [10b5-1]830$45.00$37K
2026-02-04KNSAKiniksa Pharmaceuticals International, plcM — Option exercise [10b5-1]830$15.47$13K

Companies — Last 90 Days

Frequently Asked Questions

Who is Quart Barry D?

Barry D. Quart is a prominent executive in the pharmaceutical industry, currently serving as the CEO and a director of Kiniksa Pharmaceuticals International, plc. He has extensive experience in the biotech and pharmaceutical sectors, having held various leadership roles in multiple companies. Quart has been instrumental in the development and commercialization of innovative the…

How many SEC Form 4 filings has Quart Barry D submitted recently?

2 primary Form 4 filings in the last 90 days, covering 1 company.

Has Quart Barry D been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 7 open-market sales ($1.85M) across all tracked filings.

Where can I see all of Quart Barry D's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Quart Barry D profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.